Sign in to fuzzto save your conversations, follow your research and come back anytime.
Sun Pharmaceutical
SectorHealthcare
Sun Pharmaceutical Industries Limited is a global specialty generic pharmaceutical company based in India. It manufactures and markets a wide range of pharmaceutical formulations including generics, branded generics, complex products, over-the-counter drugs, and active pharmaceutical ingredients. The company has a diverse portfolio covering multiple therapeutic areas and dosage forms. Sun Pharma has a strong presence in India and the US, which account for about 70% of its revenue. It operates 43 manufacturing facilities worldwide and invests 7-8% of revenue in R&D annually. The company has expanded through acquisitions and licensing deals to strengthen its specialty and generic portfolios. Key specialty products include Ilumya, Winlevi, Cequa and others in dermatology, ophthalmology and oncology. Sun Pharma supplies medicines to over 100 countries and has manufacturing facilities across six continents.
In the news
5 Stocks Show Consistent Score Improvement with 29% Upside Potential
Sun Pharma board approves ₹10,000 cr NCD fundraising plan
HCG calls cancer drug margin cap 'thoughtless interference' amid ₹2,500-3,500 crore savings
Sun Pharma board meets Oct 12 to consider ₹15,000 cr NCD issue for Organon
Sun Pharma Plans ₹10,000 Cr Rupee Debt Sale for Organon Loan Refinance
Azad Engineering Hits 52-Week High at ₹3,126, ICICI Securities Upgrades
US waives 100% pharma tariffs on India, 19 countries
Sun Pharma licenses PCSK9 drug from LIB Therapeutics globally
India's pharma supply chain resilience: Small-caps surge 360% amid China+1 shift
Sun Pharma subsidiaries settle US antitrust case for confidential amount
Brokerages Eye L&T, Sun Pharma, SBI Life for Trading Opportunities
Sun Pharma, Cipla offer better upside: Systematix
Sun Pharma Shares Rise 0.36% After Bernstein, HSBC Maintain Bullish Ratings
Sun Pharma wins Lipitor antitrust lawsuit appeal in US court
Sun Pharma Faces Major Legal Setback in Semaglutide Launch
Bajaj Broking picks Sun Pharma, BEL for 6-month rally
India's Outbound M&A Evolution: From Scale to Capability
Sun Pharma shares fall 2% despite strong Q1 results beating expectations
Sun Pharma Q1FY27: ₹15,183 cr revenue, target price ₹2,310
Brokerages update ratings: Tata Steel, Maruti Suzuki, GAIL
Company insights, generated from the most recent coverage.
Sun Pharma's Global Innovative Medicines business plus low debt gives it both a non-generic growth engine and balance-sheet flexibility — the combination that defines pharma defensiveness.
Settlement of US antitrust litigation caps financial exposure (est. $85-150M) and removes regulatory overhang, stabilizing US generic pricing strategy.